Arvin George, MD, highlights VAPOR 2 trial of thermal water therapy for prostate cancer

Interim data from the VAPOR 2 trial (NCT05683691) were presented at the 2025 Society of Urology Oncology Annual Meeting in Phoenix, Arizona.¹ Overall, the trial is assessing the safety and efficacy of the Vanquish System, a transurethral thermal water vapor device to treat patients with localized intermediate-risk prostate cancer.

The Vanquish System was granted FDA 510(k) clearance on Decemeber 2, 2025.²

In a recent interview with Urology Times®, presenting author Arvin K. George, MD, detailed the unique design of the VAPOR 2 trial as well as the key findings from the first 110 patients enrolled in the study. George is urologic oncologist, director of prostate cancer programs, and an associate professor of clinical urology at Johns Hopkins Medicine in Baltimore, Maryland.

At the time of data report, 110 patients were enrolled in the study. In total, the trial intends to enroll 235 patients across 26 clinical trial sites in the US.

At 6 months, 91% of eligible patients (n = 110) showed no targeted MRI visible intermediate-risk disease following a single Vanquish procedure. According to the company, “the Vanquish System demonstrated the ability to effectively treat cancerous lesions in all prostate locations, addressing a significant limitation of existing ablative options.”²

Treatment was also well-tolerated, with no device-related serious adverse events and low rates of urinary incontinence and erectile dysfunction.

REFERENCE

1. George A. Thermal water therapy for the management of prostate cancer: the VAPOR 2 study. Interim analysis. Presented at: Society of Urologic Oncology Annual Meeting; December 2-5, 2025; Phoenix, Arizona. Abstract 260. https://suo-abstracts.secure-platform.com/a/gallery/rounds/24/details/4899

2. Francis Medical Receives FDA 510(k) Clearance for Use of the Vanquish® Water Vapor System for Prostate Tissue Ablation in Patients with Intermediate Risk Prostate Cancer. News release. Francis Medical. December 2, 2025. Accessed December 8, 2025. https://www.francismedical.com/francis-medical-receives-fda-510k-clearance-for-use-of-the-vanquish-water-vapor-system-for-prostate-tissue-ablation-in-patients-with-intermediate-risk-prostate-cancer/